In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diagnostics, Meet Consumerism

Executive Summary

A few years ago, Quest Diagnostics, the nation's largest reference lab, began a pilot program offering direct access testing (DAT) in a few locations in the South and West. In DAT, the premise is that consumers are willing to pay out of pocket to obtain accurate, timely information about their health-and that laboratory tests are much less expensive than some of the other health services that are offered to the general public and not reimbursed. Recently, The American Association for Clinical Chemistry held an audioconference on DAT. Speaker Lawrence Killingsworth, PhD, the chief science and technical officer at the Sacred Heart Medical Center in Spokane, WA, spelled out the process of transforming a physician-oriented laboratory testing service into one geared towards consumers, in essence building a retail health care business.

You may also be interested in...



Kissei Discussing Rovatirelin Path After Mixed Phase III Results

Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.

QUOTED. 24 January 2020. Megan McSeveney.

The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.

A Tale Of Two DMD Drugs: Theme And Variation In Controversial US FDA Reviews

Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.

Related Companies

UsernamePublicRestriction

Register

IV001998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel